Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
The trial was terminated before any patients were exposed to the trial drug based on new findings indicating that dose escalation with multiple doses should be performed in a different trial population.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of systemic lupus erythematosus (SLE)
Disease duration: 6 months or longer
Stable, mild to moderately active systemic lupus erythematosus (SLE)
Receiving stable maintenance therapy
You may not be if
Significant Lupus Nephritis
Active central nervous system (CNS) disease
Significant arterial or venous thrombosis (blood clots) within 12 months prior to trial start
Body weight of 260 lbs/120 kg or more
History of alcohol or substance abuse
History of cancer
Infections
Viral infections: HIV, Hepatitis B or C, Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Varicella-Zoster Virus (VZV), or Herpes Simplex Virus (HSV-1 or HSV-2)
Tuberculosis
Severe systemic bacterial, viral or fungal infections within the past 12 months prior to trial start
